The activation of AMPK induces the translocation of glucose transporter 4 (GLUT4) to the plasma membrane [5], and several studies have demonstrated that AMPK and its signaling pathway are potential molecular targets in the development of drugs for the treatment of type 2 diabetes and obesity [6]–[9]. This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.